Physician profile
Brian Walsh
NPI 1902845670
$5,232.93
in general payments reported to CMS, 2019-2025
30 companies · $903 in 2025
The $903 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $587 · 2021: $658 · 2022: $992 · 2023: $995 · 2024: $823 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,721.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,403.47 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $969.96 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $384.19 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $365.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $247.90 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $234.86 | 2019-2023 | Steglatro, Belsomra, Steglujan |
| Abbott Laboratories | $214.11 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.28 | 2019-2023 | Spiriva Respimat |
| E.R. Squibb & Sons, L.L.C. | $160.96 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.56 | 2022-2024 | |
| Almatica Pharma LLC | $127.16 | 2024-2025 | Loreev Xr, Teriparatide |
| Amgen INC. | $104.32 | 2024 | Repatha, Otezla |
| Hikma Pharmaceuticals USA | $95.73 | 2020-2022 | |
| Pfizer INC. | $91.83 | 2023-2024 | |
| Allergan, INC. | $73.52 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $70.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $61.92 | 2020-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $51.59 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $36.50 | 2023 | |
| Amneal Pharmaceuticals LLC | $33.68 | 2023 | Lyvispah |
| Astellas Pharma US INC | $31.10 | 2025 | Veozah |
| Collegium Pharmaceutical, INC. | $29.69 | 2025 | Belbuca |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.45 | 2022 | |
| Esperion Therapeutics, INC. | $17.85 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.69 | 2023 | Ztlido |
| Ironwood Pharmaceuticals, INC | $16.48 | 2024 | |
| Theracosbio, LLC | $15.57 | 2023 | Brenzavvy |
| Genentech USA, INC. | $13.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.